Company intelligence / Profile preview
Glaukos Corporation
- Ownership
- Public · GKOS
- Employees
- ~800
- Development stage
- Other
Overview
Glaukos has pioneered micro-invasive glaucoma surgery with its iStent device family, which has been implanted in over a million patients. The company also markets the only FDA-approved corneal cross-linking therapy in the U.S. and continues to advance a robust pipeline of novel ophthalmic drugs and devices across all stages of development. Recent clinical milestones include completion of Phase III trials for new sustained-release intraocular pressure-lowering implants ("iDose TR") and ongoing expansion into retinal disease therapeutics. The company reinvests heavily into R&D (~30% of sales)
- Therapeutic areas
- Ophthalmology
- Modalities
- Micro-invasive surgical devices (MIGS)sustained-release drug delivery platformspharmaceuticals (including cream-based and dropless therapies)biosensors
- Industry
- Biotech
Drug pipeline
18 assets17 more assets in the full pipeline.
Partnerships
Financials
- Market cap
- $13B
- Total revenue
- $507.4M
- Enterprise value
- $12.8B
Beyond the preview
Go deeper on Glaukos Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Glaukos Corporation.